Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com

Please find enclosed a Press Release on

"Dr. Reddy's Laboratories announces the launch of

Cinacalcet Tablets in the U.S. Market."

This is for your information.

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

Laboratories announces the launch of

Cinacalcet Tablets in the U.S. Market

Hyderabad, India and Princeton, NJ, USA.

October 01, 2020 - Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together

referred to as "Dr. Reddy's") today announced the launch of Cinacalcet Tablets, a therapeutic equivalent generic

version of Sensipar (cinacalcet) Tablets, approved by the U.S. Food and Drug Administration (USFDA).

The Sensipar brand and generic market had

U.S. sales of approximately $312 million MAT for the most recent twelve months ending in July 2020 according to IQVIA Health*.

Dr. Reddy's Cinacalcet Tablets are

available in 30 mg, 60 mg, and 90 mg tablets in a bottle count size of 30.

Please see for full prescribing information.

Sensipar is a trademark of Amgen Inc.

*IQVIA Retail and Non-Retail MAT July 2020

About Dr. Reddy's: Dr. Reddy's Laboratories

Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative

medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics

and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical

services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular,

diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets

include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future

expectations and other forward-looking statements that are based on the management's current views and assumptions and involve

known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those

expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may",

"will", "should", "expects", "plans", "intends", "anticipates", "believes",

"estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking

statements. Actual results, performance or events may differ materially from those in such statements due to without limitation,

(i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates,

persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing

levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks

and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi)

the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic

downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19),

and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including

those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form

20-F for the year ended March 31, 2020. The company assumes no obligation to update any information contained herein."